IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases

Read about it here

May 17  2016

Amunix and XTEN technology featured in ‘Innovations’ on Discovery Channel TV. 

View the segment here: Amunix on Discovery TV

Sep 18  2015

Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study of Growth-Hormone-XTEN (VRS-317, Somavaratan) in Children (Amunix out-licensed VRS-317, a fusion protein consisting of rhGH and XTEN, to Versartis in 2008).

Read about it here: Versartis Study Announcement

October 2014

Launch of our new website!

We want to hear from you. How can we improve our website? Your suggestions, ideas, complaints will greatly help us.  Please send us your comments or suggestions via our contact form (Website Feedback) tab.